Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  sulindac
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-17 of 17 for your search:
Start Over
Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps
Phase: Phase III
Type: Prevention
Status: Completed
Age: 40 to 80
Sponsor: NCI
Protocol IDs: NCI-2009-00880, UCI 97-05, R01CA088078, UCIRVINE-UCI-2002-2261, NCT00118365
Phase II Clinical Trial of Sulindac, a Nonsteroidal Antiinflammatory Agent, for Chemoprevention of Colorectal Neoplasia (Summary Last Modified 05/1999)
Phase: Phase II
Type: Prevention
Status: Closed
Age: 18 to 80
Sponsor: NCI
Protocol IDs: CPMC-IRB-1095-072, NCI-P97-0110
Sulindac and Docetaxel in Treating Women With Metastatic or Recurrent Breast Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000069390, P30CA006927, FCCC-01031, FCCC-63723, NCI-G02-2080, NCT00039520
Phase II Randomized, Placebo-Controlled Trial of Sulindac for Chemoprevention of Pre-malignant Colorectal Adenomas (Summary Last Modified 12/94)
Phase: Phase II
Type: Prevention
Status: Closed
Age: 30 to 80
Sponsor:
Protocol IDs: UUMC-9102, NCI-P92-0018
Sulindac and Tamoxifen in Treating Patients With Desmoid Tumor
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and under at original diagnosis
Sponsor: NCI, Other
Protocol IDs: ARST0321, NCI-2009-00424, CDR0000322260, COG-ARST0321, U10CA098543, NCT00068419
Atorvastatin Calcium, Oligofructose-Enriched Inulin, or Sulindac in Preventing Cancer in Patients at Increased Risk of Developing Colorectal Neoplasia
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Status: Completed
Age: 40 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00837, CDR0000467755, MAY03-1-03, N01CN35000, P30CA015083, MAYO-030103, MAYO-1395-05, NCT00335504
Sulindac in Preventing Lung Cancer in Current or Former Smokers With Bronchial Dysplasia
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention, Tissue collection/Repository
Status: Completed
Age: 40 to 79
Sponsor: NCI
Protocol IDs: NCI-2009-00836, CDR0000496457, MAY03-1-02, MAYO-03-1-02, P30CA015083, N01CN35000, NCT00368927
Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 06-111, NCT00392665
Sulindac and Epirubicin in Treating Patients With Metastatic Malignant Melanoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 06-03 ICORG, ICORG-06-03, EUDRACT-2006-006051-12, EU-20876, ICORG 06-03 Epi Sulindac, NCT00755976
Sulindac in Preventing Melanoma in Healthy Participants Who Are at Increased Risk of Melanoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 to 65
Sponsor: NCI
Protocol IDs: NCI-2009-01115, UARIZ-08-0841-04, CDR0000633938, N01CN35158, 08-0841-04, UAZ05-2-10, P30CA023074, UARIZ-UAZ05-2-10, NCT00841204
Eflornithine Plus Sulindac in Preventing Colorectal Cancer in Patients With Benign Colorectal Polyps
Phase: Phase II
Type: Prevention
Status: Completed
Age: 40 to 80
Sponsor: NCI, Other
Protocol IDs: CDR0000067922, 1997-96, NCI-P00-0150, UCIRVINE-97-05, NCT00005882
A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Status: Closed
Age: 18 to 69
Sponsor: NCI, Other
Protocol IDs: 00039278, P01CA073992, NCT01187901
Phase I Study of Sulindac in Women at High Risk for Breast Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Prevention
Status: Closed
Age: 18 to 65
Sponsor: NCI
Protocol IDs: UARIZ-UAZ04-2-02, UARIZ-HSC-0553, UAZ04-2-02, NCT00245024
Sulindac in Preventing Breast Cancer in Women at High Risk for Breast Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Prevention
Status: Completed
Age: 18 to 65
Sponsor: NCI
Protocol IDs: CDR0000447144, P30CA023074, UARIZ-UAZ04-2-02, UARIZ-HSC-0553, UAZ04-2-02, NCT00245024
Randomized Placebo-Controlled, Double-Blind Study in the Prevention of Colorectal Adenocarcinoma with Sulindac in Patients with Multiple Polyposis (Summary Last Modified 10/92)
Phase: No phase specified
Type: Prevention
Status: Closed
Age: 18 and older
Sponsor: NCI
Protocol IDs: NCCTG-909251, MAYO-909251, NCI-P91-0011
Sulindac Capsules Compared With Sulindac Tablets in Healthy Volunteers
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Prevention
Status: Completed
Age: 40 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000473167, MAYO-03-1-BIO, MAYO-CPN0576, MAYO-05-004233, MAY03-1-BIO, NCT00343629
A Randomized Study of Sulindac in Oral Premalignant Lesions
Phase: No phase specified
Type: Prevention
Status: Closed
Age: Over 18
Sponsor: Other
Protocol IDs: 04-099, NCT00299195
Start Over